New drug duo aims to fight rare, spreading eye cancer
NCT ID NCT06121180
Summary
This study is testing if a combination of two drugs, cemiplimab and Ziv-aflibercept, can help control metastatic uveal melanoma, a rare cancer that starts in the eye and spreads. The main goal is to see if the treatment can shrink tumors or stop them from growing. It will involve about 32 adults whose cancer has progressed despite other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwell Health Center for Advanced Medicine
RECRUITINGNew Hyde Park, New York, 11042, United States
Contact
-
The Angeles Clinic and Research Institute
RECRUITINGLos Angeles, California, 90025, United States
Contact
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact
Conditions
Explore the condition pages connected to this study.